CSBR — Champions Oncology, Inc.

Champions Oncology (CSBR) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $15 million, up 11% year-over-year from $13.5 million.
• Income from Operations: $185,000.
• Adjusted EBITDA: Approximately $800,000, with expectations for full-year positive adjusted EBITDA.
• Gross Margin: Improved to 52%, up from 45% year-over-year, attributed to operational efficiencies and reduced cancellations.
• Operating Expenses: Increased to $7 million, up $2 million from the previous year, primarily due to strategic investments in the data platform and commercial team.
• Cash Position: Ended the quarter with $8.5 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Core Goals: Focus on revenue growth, investment in data platforms, and maintaining fiscal discipline.
• Market Environment: Gradual improvement in pharma and biotech budgets, with increased customer engagement and a positive outlook for booking momentum in 2026.
• Radiolabeling Capabilities: Continued success in this specialized area, expected to enhance gross margins as more work is brought in-house.
• Data Platform Investment: Enhancements to the data platform are ongoing, with a focus on expanding utility for pharma partners.
• Corellia Progress: Positive discussions with potential venture capital partners for Corellia, which focuses on target discovery.

3. Forward Guidance and Outlook

• The company remains optimistic about achieving year-over-year revenue growth and maintaining positive adjusted EBITDA for the full fiscal year.
• Anticipates improved operational efficiency and margin performance as the market conditions stabilize and customer demand increases.

4. Bad News, Challenges, or Points of Concern

• Operating Expense Increase: The rise in operating expenses, while strategic, may impact short-term profitability.
• Market Conditions: Although improving, the overall funding environment in biotech is still not fully restored, posing potential risks to growth.
• Corellia's Funding: Until external funding is secured, Corellia will continue to impact the P&L, which may extend through fiscal 2027.

5. Notable Q&A Insights

• Cancellations and RFPs: Management noted a return to historic levels of cancellations and an uptick in inbound requests for proposals (RFPs), suggesting a recovering market.
• Sales and Marketing Investments: New hires are primarily focused on the data opportunity, with strategic leadership added to enhance growth in this area.
• Gross Margin Expectations: Management indicated that gross margins are expected to remain stable around 50-52%, though fluctuations may occur due to variable costs associated with outsourced services.
• Corellia's Drug Candidates: Specific details on Corellia's drug candidates and IND application timelines were not disclosed, but management expressed optimism about the progress and interest from venture capitalists.

Overall, Champions Oncology is positioned for growth with strategic investments and improved operational metrics, despite facing some challenges in the broader market environment.